Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziftomenib - Kura Oncology

Next Previous
Drug Profile

Ziftomenib - Kura Oncology

Alternative Names: KO-539

Latest Information Update: 21 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan
  • Developer Kura Oncology; Kyowa Kirin; University of Michigan
  • Class 2 ring heterocyclic compounds; Amines; Antihyperglycaemics; Antineoplastics; Fluorocarbons; Indoles; Nitriles; Pyrimidines; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action KMT2A protein inhibitors; Menin inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Gastrointestinal stromal tumours; Leukaemia
  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 07 Aug 2025 Adverse events data from a phase I/II KOMET-001 trial in Acute myeloid leukaemia released by Kura Oncology
  • 07 Aug 2025 Kura Oncology completes enrolment in its phase I/II KOMET-001 trial in Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in Belgium, Canada, France, Germany, Italy, Spain, United Kingdom and USA (PO) (NCT04067336)
  • 12 Jun 2025 Efficacy and adverse events data from the phase Ia/Ib KOMET-007 trial in Acute myeloid leukemia released by Kura Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top